<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00350181</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-06112</org_study_id>
    <secondary_id>97168</secondary_id>
    <secondary_id>BMT184</secondary_id>
    <secondary_id>6112</secondary_id>
    <nct_id>NCT00350181</nct_id>
  </id_info>
  <brief_title>Sirolimus &amp; Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT</brief_title>
  <official_title>Sirolimus and Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GVHD prophylaxis of sirolimus and mycophenolate mofetil for patients undergoing matched&#xD;
      related allogeneic transplant for acute and chronic leukemia, MDS, high risk NHL and HL&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To explore the novel combination of sirolimus and mycophenolate mofetil (MMF) as graft versus&#xD;
      host disease (GVHD) prevention in HLA matched related donor blood or marrow transplantation&#xD;
      (BMT). This study will report the toxicities associated with this drug combination and also&#xD;
      explore possible correlations between specific blood cell types and antibody production&#xD;
      during this therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the incidence of grade II-IV acute GVHD with sirolimus and mycophenolate mofetil GVHD prophylaxis.</measure>
    <time_frame>D+100 post-transplant</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Hematologic Diseases</condition>
  <condition>Acute GVHD</condition>
  <arm_group>
    <arm_group_label>Regimen Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For subjects 18-60 years old with lymphoma: (BCNU+ VP-16 +CY) BCNU 15 mg / kg (maximum dose 550 mg/m² actual body weight) on day -6. VP 60 mg / kg on day 4 and CY 100 mg / kg on day -2. Followed by Sirolimus and MMF as prophylaxis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For subjects 18-50 years old with AML, ALL or CML: (VP-16 +CY+ FBI) Patients aged 18-50 years with AML, ALL or CML: FTBI 1320 cGy delivered in 11 120 cGy fractions over 4 days on days -8 through -5. VP 60 mg / kg on day -4 and CY 60 mg / kg on day -2. Followed by Sirolimus and MMF as prophylaxis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen Treatment 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For subjects 51-60 years with MDS, AML or ALL or 18-60 with MDS, secondary AML pr non-CML myeloproliferative disease: (BU+ VP-16 +CY) BU 1 mg/kg every 6 hours X 14 doses on days -9 through -6 with target concentration at steady state of X 800 ng / ml based on first dose pharmacokinetics. VP 60 mg / kg on day -5 and CY 45 mg / kg per day -2 days on day -3 and day -2. Followed by Sirolimus and MMF as prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Immunosuppressant beginning day -3 with 12 mg oral loading dose, 4 mg/day orally for adults</description>
    <arm_group_label>Regimen Treatment 1</arm_group_label>
    <arm_group_label>Regimen Treatment 2</arm_group_label>
    <arm_group_label>Regimen Treatment 3</arm_group_label>
    <other_name>rapamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMF</intervention_name>
    <description>Immunosuppressant given through IV on day 0 at 15 mg/kg twice daily ≥ 2hr after the completion for the donor cell infusion</description>
    <arm_group_label>Regimen Treatment 1</arm_group_label>
    <arm_group_label>Regimen Treatment 2</arm_group_label>
    <arm_group_label>Regimen Treatment 3</arm_group_label>
    <other_name>Mycophenolate Mofetil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCNU</intervention_name>
    <description>15 mg/kg, IV</description>
    <arm_group_label>Regimen Treatment 1</arm_group_label>
    <other_name>Carmustine</other_name>
    <other_name>BiCNU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VP-16</intervention_name>
    <description>60 mg/kg, IV</description>
    <arm_group_label>Regimen Treatment 1</arm_group_label>
    <arm_group_label>Regimen Treatment 2</arm_group_label>
    <arm_group_label>Regimen Treatment 3</arm_group_label>
    <other_name>etoposide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CY</intervention_name>
    <description>For subjects aged 18-60 with lymphoma 100 mg/kg, IV For subjects aged with AML, ALL or CML 18-50 60 mg/kg, IV For subjects aged 51-60 with MDS, AML or ALL or patients age 18-60 with MDS, secondary AML or non-CML myeloproliferative disease 45 mg/kg</description>
    <arm_group_label>Regimen Treatment 1</arm_group_label>
    <arm_group_label>Regimen Treatment 2</arm_group_label>
    <arm_group_label>Regimen Treatment 3</arm_group_label>
    <other_name>cyclophosphamide</other_name>
    <other_name>cytophosphane</other_name>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTBI</intervention_name>
    <description>1320 cGy delivered in 11 120 cGy fractions over 4 day</description>
    <arm_group_label>Regimen Treatment 2</arm_group_label>
    <other_name>total body irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BU</intervention_name>
    <description>BU 1 mg/kg every 6hr x 4 doses, IV</description>
    <arm_group_label>Regimen Treatment 3</arm_group_label>
    <other_name>busulfan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Disease Categories: (one of the following)&#xD;
&#xD;
               -  AML, age 2 - 60 years beyond 2nd remission or relapsed/refractory disease&#xD;
&#xD;
               -  AML, age 51-60 years of age, in first or subsequent remission or&#xD;
                  relapsed/refractory disease&#xD;
&#xD;
               -  AML with multilineage dysplasia&#xD;
&#xD;
               -  ALL, age 2 - 60 years beyond 2nd remission or relapsed/refractory disease&#xD;
&#xD;
               -  ALL, age 51 - 60 years in first or subsequent remission or relapsed/refractory&#xD;
                  disease&#xD;
&#xD;
               -  CML Beyond 2nd chronic phase or in blast crisis&#xD;
&#xD;
               -  MDS; Includes World Health Organization classifications of refractory anemia with&#xD;
                  excess blasts-1 (RAEB-1), RAEB-2 and therapy-related MDS&#xD;
&#xD;
               -  Myeloproliferative disorders; MDS with poor long-term survival including myeloid&#xD;
                  metaplasia and myelofibrosis&#xD;
&#xD;
               -  High risk NHL in first remission&#xD;
&#xD;
               -  Relapsed or refractory NHL&#xD;
&#xD;
               -  HL beyond first remission&#xD;
&#xD;
          -  Males and females of any ethnic background 2 - 60 years of age&#xD;
&#xD;
          -  Karnofsky Performance Status ≥ 70% or Lansky performance status &gt; 70% for patients &lt;&#xD;
             16 years of age.&#xD;
&#xD;
          -  Matched related donor identified: 6/6 HLA-A, B and DRB1&#xD;
&#xD;
          -  Willingness to take oral medications during the transplantation period&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior myeloablative allogeneic or autologous HCT&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Lactating females&#xD;
&#xD;
          -  Evidence of uncontrolled active infection&#xD;
&#xD;
          -  Organ Dysfunction:&#xD;
&#xD;
          -  Serum creatinine &gt; 1.5 mg/dL or 24 hour creatinine clearance &lt; 50 ml/min&#xD;
&#xD;
          -  Direct bilirubin, ALT or AST &gt; 2 x ULN&#xD;
&#xD;
          -  In adults DLCO &lt; 60% predicted and in children room air oxygen saturation &lt; 92%&#xD;
&#xD;
          -  In adults, left ventricular ejection fraction &lt; 45% and in children, shortening&#xD;
             fraction &lt; 26%&#xD;
&#xD;
          -  Fasting Cholesterol &gt; 300 mg/dL or Triglycerides &gt; 300 mg/dL while on lipid-lowering&#xD;
             agents.&#xD;
&#xD;
          -  Patients receiving investigational drugs unless cleared by the PI.&#xD;
&#xD;
          -  Patients with prior malignancies except basal cell carcinoma or treated carcinoma&#xD;
             in-situ.&#xD;
&#xD;
          -  Cancer treated with curative intent &gt; 5 years will be allowed.&#xD;
&#xD;
          -  Cancer treated with curative intent ≤ 5 years will not be allowed with PI approval.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Johnston</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Sheehan K, Lavori P, Negrin R. Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant. 2012 Apr;47(4):581-8. doi: 10.1038/bmt.2011.104. Epub 2011 May 9.</citation>
    <PMID>21552302</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 5, 2006</study_first_submitted>
  <study_first_submitted_qc>July 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2006</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Laura Johnston</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

